CN-119015292-B - Application of lupeone in preparation of psoriasis treatment drugs

Abstract

The invention discloses application of lupeone in preparation of a medicament for treating psoriasis, and relates to the technical field of pharmacology. According to the invention, lupeone is adopted to treat psoriasis, the number of regulatory T lymphocytes, namely CD4 + Foxp3 + Tregs cells, in the body of a psoriasis patient can be regulated, the CD3 positive expression and inflammatory factor level in skin damage tissues of the psoriasis patient can be reduced, the immune effect of the psoriasis patient can be regulated, and further the psoriasis can be treated, and the invention is particularly characterized in that the severity of the psoriasis can be reduced, the red spots, scales and infiltration degree of skin damage can be improved, the PASI (psoriasis area and severity index) score of the skin damage can be obviously reduced, the thickness of the epidermis at the skin damage can be reduced, the hyperplasia of the epidermis can be inhibited, the hyperkeratosis and the hypokeratosis can be improved, and the acanthosis can be improved.

Inventors

• LIU HUAZHEN
• CHEN JIAYING
• DAI ZHENHUA

Assignees

• 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院）

Dates

Publication Date

20260505

Application Date

20240829

Claims (1)

1. 1. Use of lupeone in preparing medicine for treating psoriasis is provided.

Description

Application of lupeone in preparation of psoriasis treatment drugs Technical Field The invention relates to the technical field of pharmacology, in particular to application of lupeone in preparation of a medicament for treating psoriasis. Background Psoriasis is an immune-mediated chronic inflammatory disease that is associated with T cell mediated immune and inflammatory responses, as well as the pathogenesis of many major diseases including arthritis, obesity-metabolic syndrome, cardiovascular disease, and malignancies (including renal, breast, lung and colon cancers, etc.). Psoriasis thus places a serious psychological or physiological burden on the patient. About 2% of the world's people suffer from psoriasis, the most common autoimmune skin disorder in adults. Prior studies found that Foxp3 + Treg cell numbers in peripheral blood of psoriatic patients were increased and that their increase was positively correlated with the psoriasis disease activity Index (Psoriasis ACTIVITY AND SEVERITY Index, PASI). CD4 +CD25+Foxp3+ Treg cells also appear at psoriasis lesions and, similar to peripheral blood, the lesions biopsies are higher than control or healthy side skin biopsies. These findings indicate that regulatory T lymphocytes (Regulatory T cells, tregs) play a role in the pathogenesis of psoriasis. However, how to inhibit the onset of psoriasis by modulating Treg cells has not been studied at present. Disclosure of Invention According to one aspect of the present invention there is provided the use of lupeone in the manufacture of a medicament for the treatment of psoriasis. The applicant of the present invention has surprisingly found that lupeone has a remarkable therapeutic effect on psoriasis, and can significantly reduce the severity of psoriasis, improve erythema, scaling and infiltration of skin lesions, significantly reduce the PASI (psoriasis area and severity index) score of skin lesions, reduce the thickness of the epidermis at skin lesions and inhibit epidermal hyperplasia, improve hyperkeratosis and hypokeratosis, improve acanthosis and improve weight loss. This is because lupeone significantly induces an increase in the number of regulatory T cells (Tregs, in particular CD4 +Foxp3+ Tregs cells) in the spleen and lymph nodes, thereby modulating the immune effect in psoriatic patients and effecting the treatment of immune-mediated psoriasis. In some embodiments, the use is the use of lupeone in the manufacture of a medicament for psoriasis having one or more of improving the extent of erythema, scaling and infiltration thickness of skin lesions, reducing the PASI score of skin lesions, reducing the thickness of the epidermis at skin lesions and inhibiting hyperplasia of the epidermis, improving hyperkeratosis, hypokeratosis, and improving acanthosis. In some embodiments, lupeone is administered in an amount of 100 mg/kg body weight/day in the psoriasis treatment drug. According to another aspect of the invention there is provided the use of lupeone in the manufacture of a medicament for increasing the number of regulatory T lymphocytes in vivo. In some embodiments, the above-described use is the use of lupeone in the manufacture of a medicament for increasing the number of regulatory T lymphocytes in the spleen and/or lymph nodes. In some embodiments, the regulatory T lymphocytes described above are CD4 +Foxp3+ Tregs cells. Wherein the CD4 +Foxp3+ Tregs cells are differentiated from CD4 +CD25- T cells. According to another aspect of the invention there is provided the use of lupeone in the manufacture of a medicament for reducing CD3 positive expression in psoriatic skin lesion tissue. Compared with the prior art, the invention has the following beneficial effects: The invention discovers that lupeone has remarkable treatment effect on the mice psoriasis induced by imiquimod for the first time. According to the invention, lupeone is used for treating psoriasis, the number of regulatory T lymphocytes, namely CD4 +Foxp3+ Tregs cells, in the body of a psoriasis patient can be up-regulated, the positive expression of CD3 and the inflammatory factor level in skin damage tissues of the psoriasis patient can be reduced, the inflammatory cell infiltration condition in skin tissues can be improved, the immune effect of the psoriasis patient can be regulated, further, the psoriasis can be treated, the severity of the psoriasis can be obviously reduced, the PASI score of the skin damage and the skin thickness at the skin damage position can be reduced, the hyperplasia of the epidermis can be inhibited, and the lupeone has the characteristics of low side effect and good safety. Drawings FIG. 1 is a photograph of the back skin lesions of different groups of mice in the experiments of the present invention. Figure 2 is a PASI score for different groups of mice in the experiments of the invention. FIG. 3 is HE staining of skin tissue of different groups of mice in the experiments of the invention. FIG. 4 sh